Ann: Mayne Pharma provides update on Women's Health pipeline, page-41

Don’t know why MYX does not want to provide anything that investors may interest in. Below are from Mithra. Could any company be more disappointing than MYX?
Mithra’s US partner Mayne Pharma receives complete response letter from FDA for Myring™ requesting additional data that is not normally requested for generic productsBased on the information available to date, Mithra expects to have the necessary data in hand to respond to FDA before year-endNo questions or comments have been raised by FDA with regard to Mithra CDMO, which provides comfort regarding robustness of manufacturing processMid-cycle review with FDA regarding the New Drug Application (NDA) for Estelle (Nextstellis) raised no substantive issuesSolid cash position and funding facilities to cover working capital needs